The S&P 500 is having a pretty good run. Up 17% over the past year and 2.5% in the last month alone, the index recently pushed past 6,950, with 7,300 looking entirely plausible. That's the kind of performance that makes market watchers happy.

But here's the thing about index gains: they don't lift all boats equally. Some stocks in the S&P 500 are facing headwinds that could make them serious underperformers in 2026. Whether it's economic pressures, sector-specific troubles, or just bad timing, certain names look vulnerable enough to consider selling.

And according to Wall Street observers, there's a meaningful shift happening right now.

"There's certainly a rotation underway," said Ilir Salihi, founder and senior editor at IncomeInsider.org. "We're seeing mega-cap tech stocks cool while overall breadth is improving across the index."

Salihi pointed to January 14 as a telling example: more than half the S&P 500 rose even as the index itself dropped and the Magnificent 7 underperformed. "That's a healthy signal for the market, as the one-sector dominance that defined most of 2025 is giving way to a more diverse and likely more sustainable scope of growth across small caps and energy stocks."

Consensus forecasts show modest upside for the S&P 500 in 2026, but valuation metrics are elevated by historical standards, and volatility keeps rattling investors. That's creating an environment where trimming certain positions makes sense.

"Through mid-January, the S&P 500 is still slightly positive year-to-date, but we're already seeing how quickly sentiment rotates, driven in large part by banks/earnings, rate expectations, and 'priced-perfect' technology stocks," said Dr. Peter Klein, founder at Fairvalue-Calculator, a stock valuation and portfolio analysis platform. "The big takeaway: concentration risk is still huge, as a few names can drive the index, both up and down."

So which S&P 500 stocks look most vulnerable? Here are three worth considering as potential sells.

Tesla: Competition and Delivery Troubles

Tesla Inc. (TSLA) is trading around $440 per share, down about 9% over the last month. That could be a healthy pullback, or it could signal something more sustained.

"TSLA is facing rising price pressures and accelerating competition, both domestic and overseas, particularly from China's BYD (OTCPK:BYDDY)," Salihi said. "Last year, deliveries fell by about 8.6% year over year, and the Cybertruck is badly underperforming expectations in sales volume."

Major institutional holders are already backing away. The ARK Innovation ETF (ARKK), which counts Tesla as roughly 10% of its portfolio, recently sold 86,139 shares. Meanwhile, Chinese electric vehicle maker BYD Co has overtaken Tesla in the EV race, with demand for its vehicles climbing.

There's also the matter of expectations. Tesla has benefited from enthusiastic supporters who project aggressive growth, but that optimism may be getting harder to justify.

"For Tesla, pricing pressure + margin sensitivity makes the risk and reward issues less attractive versus its already-high expectations," Klein noted.

GE HealthCare Technologies: China Weakness and Competitive Pressure

GE HealthCare Technologies (GEHC) has struggled with declining sales in China, posting year-over-year decreases of approximately 11% and 18% in the first and second quarters of 2024, respectively, according to analysis.

Currently trading at $82 per share and flat over the past month, GEHC was recently downgraded by UBS, which cited competitive pressures and rising generics risk that analysts believe aren't fully reflected in the stock price.

The Chicago-based medical technology company has built solid market share in imaging and ultrasound equipment, but its stock is trading near all-time highs despite mounting threats to profitability. Its core product lines face increasing competition from the broader med tech market, suggesting limited upside and real downside risk.

If there's a reason to hold on, it's the dividend, though that's not much of a lifeline. The payout has held steady over the past five quarters but currently offers a forward yield of just 0.18%.

UnitedHealth: Policy Risk and Margin Compression

2025 was rough for UnitedHealth (UNH), the Eden Prairie, Minnesota-based healthcare coverage giant. Rising medical costs and industry headwinds forced management to cut earnings guidance last spring before abandoning it entirely a month later. The stock plummeted 45% at one point and remains down 34% over the past year.

Trading at less than $340 per share, UnitedHealth now faces projected declines in its Medicaid margins, which are expected to fall from -0.1% in 2025 to -1.8% in 2026. That deterioration is largely driven by the termination of approximately 300,000 lives following new Medicaid work requirements, according to analysts.

"With UNH, there's just enough uncertainty to wait for clearer visibility," Salihi noted. "As it stands, UnitedHealth faces a lot of headline and policy risk as Medicare Advantage plans are retrenched in many counties in 2026, and the company is facing new Senate scrutiny of 'aggressive' diagnosis practices. To minimize risk, I'd sell and reassess next year."

What Warning Signs Should Investors Watch?

Investors looking for red flags have plenty of indicators to monitor.

"The focus should be on the deteriorating fundamentals, such as units, margins, or occupancy rates going the wrong way," Salihi said. "Next, look at rising policy or regulatory overhangs that could impede growth. For instance, antitrust suits in the tech world or disruptive healthcare reimbursement policies in the insurance sector."

So what signals that it's time to exit a position?

"When valuation stops making sense versus realistic growth, margins start eroding, management pivots become defensive, or a stock needs 'perfect news' just to hold its price, that's often the exit signal," Klein said.